KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Average (2016 - 2025)

Historic Equity Average for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $6.0 billion.

  • Biomarin Pharmaceutical's Equity Average rose 1293.62% to $6.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 1293.62%. This contributed to the annual value of $5.3 billion for FY2024, which is 1103.99% up from last year.
  • Biomarin Pharmaceutical's Equity Average amounted to $6.0 billion in Q3 2025, which was up 1293.62% from $5.9 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Equity Average peaked at $6.0 billion during Q3 2025, and registered a low of $4.1 billion during Q1 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Equity Average value was $4.7 billion (recorded in 2023), while the average stood at $4.9 billion.
  • The largest annual percentage gain for Biomarin Pharmaceutical's Equity Average in the last 5 years was 2995.23% (2021), contrasted with its biggest fall of 455.79% (2021).
  • Biomarin Pharmaceutical's Equity Average (Quarter) stood at $4.3 billion in 2021, then increased by 7.5% to $4.6 billion in 2022, then increased by 7.38% to $4.9 billion in 2023, then increased by 12.42% to $5.5 billion in 2024, then increased by 9.14% to $6.0 billion in 2025.
  • Its Equity Average was $6.0 billion in Q3 2025, compared to $5.9 billion in Q2 2025 and $5.7 billion in Q1 2025.